Related Experiment Video
Updated: Jun 24, 2026

Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
Published on: February 9, 2024
Cisplatin-induced nitrosylation of p53 prevents its mitochondrial translocation
Emma Hernlund1, Ozgur Kutuk, Huveyda Basaga
1Department of Oncology-Pathology, CCK, Karolinska Institute, S-17176 Stockholm, Sweden.
Abstract:
The cellular response to DNA damage has been reported to involve rapid transcription-independent translocation of p53 to mitochondria. We show here that the DNA-damaging cisplatin-derived anticancer agent oxaliplatin induced both mitochondrial translocation and subsequent Bcl-xL interaction, whereas cisplatin did neither. The differential response was due to nitrosative modification of p53. Thus, cisplatin, but not oxaliplatin, induced increased expression of inducible nitric oxide synthase (iNOS). Cisplatin treatment in the presence of an iNOS inhibitor (1400W) allowed p53 mitochondrial translocation. Conversely, oxaliplatin-induced translocation of p53 was prevented by cotreatment with an exogenous NO donor. In cisplatin-treated cells, nuclear but not mitochondrial p53 showed nitrotyrosinylation that was inhibitable by 1400W. We conclude that nitrosative protein modification is more prominent in the response to cisplatin than oxaliplatin and that nitrosative modification of p53 is a major determinant of p53 subcellular location.
Insights
Oxaliplatin, unlike cisplatin, triggers p53 mitochondrial translocation via nitrosative modification. This modification, influenced by inducible nitric oxide synthase (iNOS), dictates p53
Area of Science:
- Molecular Biology
- Cellular Biology
- Cancer Research
Background:
- DNA damage response involves p53 translocation to mitochondria.
- The anticancer drugs cisplatin and oxaliplatin have distinct cellular effects.
Purpose of the Study:
- To investigate the differential effects of oxaliplatin and cisplatin on p53 subcellular localization.
- To elucidate the role of nitrosative modification in p53 mitochondrial translocation.
Main Methods:
- Cellular treatment with oxaliplatin and cisplatin.
- Assessment of p53 mitochondrial translocation and Bcl-xL interaction.
- Analysis of inducible nitric oxide synthase (iNOS) expression and activity.
- Investigation of nitrosative protein modification (nitrotyrosinylation).
Main Results:
- Oxaliplatin induced p53 mitochondrial translocation and Bcl-xL interaction; cisplatin did not.
- Differential response attributed to nitrosative modification of p53.
- Cisplatin, but not oxaliplatin, increased iNOS expression.
- iNOS inhibition restored oxaliplatin-induced p53 translocation, while NO donation blocked it.
- Nitrotyrosinylation of p53 was observed in cisplatin-treated cells.
Conclusions:
- Nitrosative protein modification plays a key role in the cellular response to DNA-damaging agents.
- Nitrosative modification of p53 is a critical determinant of its subcellular localization.
- Distinct mechanisms govern p53 translocation in response to cisplatin versus oxaliplatin.
Related Concept Videos
Abnormal Proliferation
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Translocation of Proteins into the Mitochondria
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Negative Regulator Molecules

